In this study, we verified the marked inhibition for critical fatty acid biosynthesis-related enzymes ACC and FAS in the NAFLD mouse models (Figure 4), which was consistent with the results in HepG2 cells directly treated with berberine (Cao et al., 2013). Here, FAS is linked to metabolic dysfunction-associated steatotic liver disease.